Antiplatelet drugs for ischemic stroke prevention

Cerebrovascular Diseases

Volumn 27, Issue SUPPL. 1, 2009, Pages 120-125

  Leys, Didier ^a,b   Balucani, Clotilde ^a   Cordonnier, Charlotte ^a  

^a UNIV LILLE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Antiplatelets; Aspirin; Ischemic stroke prevention; Nonvalvular atrial fibrillation

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; HEPARIN; PLACEBO; TICLOPIDINE; TRIFLUSAL; WARFARIN;

ATHEROMA; ATHEROSCLEROTIC PLAQUE; BLEEDING; BRAIN ATHEROSCLEROSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CAROTID ARTERY SURGERY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; HEADACHE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INCIDENCE; LOADING DRUG DOSE; NONVALVULAR ATRIAL FIBRILLATION; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; SECONDARY PREVENTION; STENOSIS; STROKE; TRANSIENT ISCHEMIC ATTACK; TREATMENT CONTRAINDICATION;

AGED; ANTICOAGULANTS; ASPIRIN; BRAIN ISCHEMIA; DIPYRIDAMOLE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; RISK ASSESSMENT; SECONDARY PREVENTION; STROKE; TICLOPIDINE; TREATMENT OUTCOME;

EID: 64149121620     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000200449     Document Type: Conference Paper

References (49)

1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ: Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006;367:1747-1757.
2. Rothwell PM, Coull AJ, Silver LE, Fairhead JF, Giles MF, Lovelock CE, Redgrave JN, Bull LM, Welch SJ, Cuthbertson FC, Binney LE, Gutnikov SA, Anslow P, Banning AP, Mant D, Mehta Z: Population-based study of eventrate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet 2005;366:1773-1783.
3. O'Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, Bowler JV, Ballard C, DeCarli C, Gorelick PB, Rockwood K, Burns A, Gauthier S, DeKosky ST: Vascular cognitive impairment. Lancet Neurol 2003;2: 89-98.
4. Hankey GJ, Warlow CP: Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations. Lancet 1999;354:1457-1463.
5. The European Stroke Organization (ESO) Executive Committee and the ESO Writing Committee: Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008;25:457-507.
6. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, Warlow C, Hafner B, Thompson E, Norton S: Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 1988;296:313-316.
7. Steering Committee of the Physicians' Health Study Research Group: Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989;321:129-135.
8. ETDRS Investigators: Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early treatment diabetic retinopathy study report 14. JAMA 1992; 268:1292-1300.
9. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755-1762.
10. de Gaetano G: Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001;357:89-95.
11. Iso H, Hennekens C, Stampfer M, Rexrode K, Colditz G, Speizer F, Willett W, Manson J: Prospective study of aspirin use and risk of stroke in women. Stroke 1999;30:1764-1771.
12. Bartolucci A, Howard G: Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin. Am J Cardiol 2006;98:746-750.
13. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE: A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293-1304.
14. Felmeden DC, Lip GY: Antithrombotic therapy in hypertension: a Cochrane systematic review. J Hum Hypertens 2005;19:185-196.
15. Bhatt D, Fox K, Hacke W, Berger P, Black H, Boden W, Cacoub P, Cohen E, Creager M, Easton J, Flather M, Haffner S, Hamm C, Hankey G, Johnston S, Mak K, Mas J, Montalescot G, Pearson T, Steg P, Steinhubl S, Weber M, Brennan D, Fabry-Ribaudo L, Booth J, Topol E: Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-1717.
16. Hobson R 2nd, Krupski W, Weiss D: Influence of aspirin in the management of asymptomatic carotid artery stenosis. VA Cooperative Study Group on Asymptomatic Carotid Stenosis. J Vasc Surg 1993;17:257-263.
17. Engelter S, Lyrer P: Antiplatelet therapy for preventing stroke and other vascular events after carotid endarterectomy (review). Cochrane Database Syst Rev 2003;3:CD001458.
18. Hart RG, Pearce LA, Aguilar MI: Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atria l fibrillation. Ann Intern Med 2007;146:857-867.
19. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Levy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Gregoratos G, Hiratzka LF, Jacobs AK, Russell RO, Smith SC Jr, Alonso-Garcia A, Blomstrom-Lundqv ist C , de Backer G, Flather M, Hradec J, Oto A, Parkhomenko A, Silber S, Torbicki A: ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation 2001;104:2118-2150.
20. Connolly S, Pogue J, Hart R, Pfeffer M, Hohnr S, Yusuf S: Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. La ncet 2006;367:1903-1912.
21. Mayo Asymptomatic Carotid Endarterectomy Study Group: Results of a randomized controlled trial of carotid endarterectomy for asymptomatic carotid stenosis. Mayo Clin Proc 1992;67:513-518.
22. Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71-86.
23. Algra A, van Gijn J: Aspirin at any dose above 30 mg offers only modest protectionafter ce rebral ischaemia. J Neurol Neurosurg Psychiatry 1996; 60:197-199.
24. The Dutch TIA Trial Study Group: A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991; 325:1261-1266.
25. Farrell B, Godwin J, Richards S, Warlow C: The United Kingdom Transient Ischaemic Attack (UK-TIA) Aspirin Trial: final results. J Neurol Neurosurg Psychiatry 1991; 54:1044-1054.
26. Campbell C, Smyth S, Montalescot G, Steinhubl S: Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 20 07; 297: 2018-2024.
27. Chimowitz M, Lynn M, Howlett-Smith H, Stern B, Hertzberg V, Frankel M, Levine S, Chaturvedi S, Kasner S, Benesch C, Sila C, Jovin T, Romano J: Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005; 352:1305-1316.
28. Matias-Guiu J, Ferro JM, Alvarez-Sabin J, Torres F, Jimenez MD, Lago A , Melo T:Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: The TACIP Study: a randomized, double-blind, multicenter trial. Stroke 2003;34:840-848.
29. Costa J, Ferro JM, Matias-Guiu J, Alvarez-Sabin J, Torres F: Triflusal for preventing serious vascular events in people at high risk. Cochrane Database Syst Rev 2005: CD004296.
30. Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, Panak E, Roberts RS, Sicurella J, Turpie AG: The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989;1:1215-1220.
31. Hass WK, Easton JD, Adams HP Jr, Pryse-Phillips W, Molony BA, Anderson S, Kamm B: A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989;321:501-507.
32. CAPRIE Steering Committee: A Randomised, Blinded Trial of Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE). Lancet 1996;348:1329-1339.
33. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A: European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13.
34. Halkes P, van Gijn J, Kappelle L, Koudstaal P, Algra A: Aspirin plus Dipyridamole versus Aspirin Alone after Cerebral Ischaemia of Arterial Origin (ESPRIT): randomised controlled trial. Lancet 2006;367:1665-1673.
35. Chang YJ, Ryu SJ, Lee TH: Dose titration to reduce dipyridamole-related headache. Cerebrovasc Dis 2006;22:258-262.
36. Diener H, Davidai G: Dipyridamole and headache. Future Neurol 2007;2:279-283.
37. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, Vandermaelen C, Voigt T, Weber M, Yoon BW; PRoFESS Study Group: Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008;359:1238-1251.
38. Diener H, Bogousslavsky J, Brass L, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht H: Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331-337.
39. Yusuf S, Zhao F, Mehta S, Chrolavicius S, Tognoni G, Fox K, the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345: 494-502.
40. EAFT (European Atrial Fibrillation Trial) Study Group: Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-1262.
41. Deplanque D, Leys D, Parnetti L , Schmidt R, Ferro J, de Reuck J, Mas JL, Gallai V: Secondary prevention of stroke in patients with atrial fibrillation: factors influencing the prescription of oral anticoagulation at discharge. Cerebrovasc Dis 2006;21:372-379.
42. Deplanque D, Leys D, Parnetti L , Schmidt R, Ferro J, De Reuck J, Mas JL, Gallai V: Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study. Br J Clin Pharmacol 2004;57:798-806.
43. Homma S, Di Tullio MR, Sciacca RR, Sacco RL, Mohr JP: Effect of aspirin and warfarin therapy in stroke patients with valvular strands. Stroke 2004;35:1436-1442.
44. Weimar C, Kraywinkel K, Rodl J, Hippe A, Harms L, Kloth A, Diener HC: Etiology, duration, and prognosis of transient ischemic attacks: an analysis from the German Stroke Data Bank. Arch Neurol 2002;59:1584-1588.
45. International-Stroke-Trial-Collaborative-Group: The International Stroke Trial (IST): A randomised trial if aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997;349:1569-1581.
46. CAST-Collaborative-Group: CAST: Randomised placebo-controlled trial of early aspirin use in 20000 patients with acute ischeaemic stroke. Lancet 1997;349:1641-1649.
47. AbESTT Investigators: Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized phase 2 trial. Stroke 2005;36:880-890.
48. Adams HP Jr, Effron MB, Torner J, Davalos A, Frayne J, Teal P, Leclerc J, Oemar B, Padgett L, Barnathan ES, Hacke W: Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Tria l (AbESTT-II). Stroke 2008;39:87-99.
49. Brainin M, Barnes M, Baron JC, Gilhus NE, Hug hes R, Selmaj K, Wa ldema r G: Guida nce for the preparation of neurological management guidelines by EFNS scienti fic task forces - revised recommendations 2004. Eur J Neurol 2004;11:577-581.